2007 Annual General Meeting: Shareholders approve all motions of the Board; Motions of BB Medtech rejected

Zurich, Switzerland, April 19th 2007 – At the Annual General Meeting of the shareholders of the Tecan Group AG, all motions of the Board of Directors were approved. The shareholders authorized a doubling of the payout to shareholders comprised of an ordinary dividend of CHF 0.45 and a reduction in nominal value of CHF 0.45 per share. In addition, one year terms for the Board of Directors were approved. Peter Ryser was reelected as member of the Board and Heinrich Fischer and Jürg Meier elected as new members of the Board. All personnel related motions of BB Medtech / BB Medhealth were rejected.

The shareholders adopted the annual report, the annual financial statements, and the consolidated financial statements, and granted the discharge to the Board of Directors. In addition, the shareholders approved a reduction in the nominal value of the share capital which enabled the doubling of the payout to the shareholders. KPMG AG, Zurich, was confirmed as the company’s auditor for the 2007 fiscal year.

All personnel related motions by BB Medtech / BB Medhealth, which would have amounted to a radical change in the composition of the Board of Directors, were rejected by the shareholders. The Board views this as a strong vote of confidence in the proven leadership structure under chairman Mike Baronian.

About Tecan

Tecan (www.tecan.com) is a leading global supplier of solutions for the biopharma, forensic and diagnostic industries. The company is a leader in the development, production and distribution of advanced automation and detection solutions for the world’s leading life science laboratories. Through its REMP subsidiary (www.remp.com), Tecan is the premier supplier of large-scale automated laboratory storage and logistics systems. Founded in Switzerland in 1980, the company has over 1100 employees, owns production, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2006, Tecan achieved sales of CHF 405.9 million (USD 324.7 million; EUR 258.6 million). Shares of the Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Valor: 1210019).

For further information please contact:

Tecan Group Ltd.
Investors Relations
Seestrasse 103
8708 Maennedorf
Switzerland

T +41 44 922 84 30
F +41 44 922 88 89
investor@tecan.com
www.tecan.com